Rheumatology

Back to articles

Methotrexate monotherapy good choice for early, poor-prognosis RA

KEY POINT

Patients with early, poor-prognosis rheumatoid arthritis (RA) who received initial methotrexate (MTX) monotherapy with the option to step up to combination therapy had similar outcomes at 2 years to those started on combination therapies. Approximately 30% of MTX monotherapy patients achieved low levels of disease activity without stepping up to combination therapy.